logo-loader

Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association

Published: 08:19 15 Jun 2020 EDT

Arecor Limited's Sarah Howell speaks to Proactive's Andrew Scott after the company presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, to the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting.

AT247 has been formulated to accelerate insulin absorption, post-injection, to enable more effective management of blood glucose levels.

Howell says the next step will be to explore AT247’s potential as the ideal insulin for use in a pump and fully closed-loop delivery (artificial pancreas) systems.

FTSE 100 awaits Rishi Sunak’s Budget today while oil majors rise with higher...

FTSE 100 opened higher helped by a strong start from the oil majors BP and Shell as more brokers predicted crude prices are going to rise higher. Attention will focus on Rishi Sunak’s Budget later today but for now the index is up 38 at 7,515.   Sunak’s announcement comes just after UK...

on 03/23/2022